ASH2015

Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLL

Idelalisib With Bendamustine and Rituximab Superior to Bendamustine and Rituximab alone for Relapsed/Refractory CLL

By

For patients with relapsed/refractory CLL, the addition of idelalisib to bendamustine and rituximab can prove more beneficial than the latter two drugs alone, recent study data suggest.

Study Details Economic Burden of Relapsed/Refractory Multiple Myeloma

Study Details Economic Burden of Relapsed/Refractory Multiple Myeloma

By

A recent study examined the direct and indirect costs for patients with relapsed or refractory multiple myeloma.

Pretransplant Myeloablative Regimens Confirmed Standard of Care for MDS, AML

Pretransplant Myeloablative Regimens Confirmed Standard of Care for MDS, AML

By

Results of a phase 3 randomized trial support high intensity conditioning with myeloablative regimens prior to allogeneic stem cell transplantation as standard of care for patients with acute myeloid leukemia.

Venetoclax Induces Deep Remissions in Ultra-High Risk Relapsed/Refractory CLL with 17p Deletion

Venetoclax Induces Deep Remissions in Ultra-High Risk Relapsed/Refractory CLL with 17p Deletion

By

Treatment with venetoclax monotherapy may be a viable option for some high-risk patients with relapsed/refractory chronic lymphocytic leukemia.

Among Medicare Beneficiaries with MDS, No Association Between Costs of Care, Overall Survival

Among Medicare Beneficiaries with MDS, No Association Between Costs of Care, Overall Survival

By

Overall survival rates for Medicare beneficiaries with myelodysplastic syndrome (MDS) showed little difference related to disease-related costs, according to data presented at the 2015 ASH Annual Meeting in Florida.

Negative PET Scan Post-ABVD: No Need for RT in Advanced Stage Classical Hodgkin Lymphoma

Negative PET Scan Post-ABVD: No Need for RT in Advanced Stage Classical Hodgkin Lymphoma

A PET-guided approach may reduce the need for additional radiotherapy in some patients with advanced classical Hodgkin lymphoma.

CAR T cells Can Have Powerful Activity in Multiple Myeloma

CAR T cells Can Have Powerful Activity in Multiple Myeloma

By

In the first clinical trial of an anti-B-cell maturation antigen chimeric antigen receptor (CAR-BCMA), a strong anti-myeloma response was observed.

PET Can Guide Subsequent Treatment in Advanced Stage Hodgkin Lymphoma

PET Can Guide Subsequent Treatment in Advanced Stage Hodgkin Lymphoma

By

PET deemed safe for use after two cycles of BEACOPPesc chemotherapy for advanced stage Hodgkin lymphoma, according to a recent study.

More Sustainable Pricing Needed for Oral Treatments for Chronic Lymphocytic Leukemia

More Sustainable Pricing Needed for Oral Treatments for Chronic Lymphocytic Leukemia

By

The high cost of for first-line oral targeted therapies for chronic lymphocytic leukemia needs to be addressed, based on model data examining CLL prevalence and patient affordability.

COG: Immunophenotypic Expression Profiles Can Help Predict Outcome in AML

COG: Immunophenotypic Expression Profiles Can Help Predict Outcome in AML

By

Immunophenotypic expression profiles can provide a tool to discriminate cohorts of young patients with acute myeloid leukemia (AML) that have a high relapse probability.

Extended Dosing of Oral Azacitidine Safe in Acute Myeloid Leukemia

Extended Dosing of Oral Azacitidine Safe in Acute Myeloid Leukemia

By

An oral formulation of azacitidine was safe and clinically active in patients with acute myeloid leukemia (AML), according to results presented at the 57th American Society of Hematology Annual Meeting.

Allogeneic SCT: A Curative Strategy for Primary Refractory AML

Allogeneic SCT: A Curative Strategy for Primary Refractory AML

By

For patients with refractory acute myeloid leukemia (AML), employment of allogeneic stem cell transplantation may be a valid treatment strategy.

Arsenic Trioxide Reduces Relapse in Standard Risk Newly Diagnosed APL

Arsenic Trioxide Reduces Relapse in Standard Risk Newly Diagnosed APL

By

Arsenic trioxide can lower relapse rates in first-line treatment of standard risk acute promyelocytic leukemia (APL), but proper administration is required.

Ponatinib Ups Overall Survival in Patients with CP-CML and T315I Mutation

Ponatinib Ups Overall Survival in Patients with CP-CML and T315I Mutation

By

For patients with chronic phase chronic myeloid leukemia (CP-CML) and the T315I mutation, ponatinib treatment may offer longer overall survival.

No Survival Benefit to Fourth Chemo Course in Younger Patients with AML

No Survival Benefit to Fourth Chemo Course in Younger Patients with AML

By

Although a fourth chemotherapy course may benefit younger patients with poor-risk acute myeloid leukemia, those with good and standard risk demonstrated little survival benefit from the additional course.

Addition of Midostaurin Significantly Improved Event-Free and Overall Survival in Some Patients With Acute Myeloid Leukemia

Addition of Midostaurin Significantly Improved Event-Free and Overall Survival in Some Patients With Acute Myeloid Leukemia

By

The addition of midostaurin, a multi-target protein kinase inhibitor, to to standard chemotherapy for AML has been associated with increased survival.

Antibiotic Prophylaxis During Induction Phase Reduces Infections in Pediatric ALL

Antibiotic Prophylaxis During Induction Phase Reduces Infections in Pediatric ALL

By

Continuous antibiotic treatment can reduce infections in young patients with acute lymphoblastic leukemia (ALL).

Fractures Higher in Non-Hispanic Patients Treated for Newly Diagnosed Pediatric ALL

Fractures Higher in Non-Hispanic Patients Treated for Newly Diagnosed Pediatric ALL

By

Non-Hispanic children undergoing treatment for newly diagnosed acute lymphoblastic leukemia reported higher rates of fractures and opportunistic infections, according to new study data.

Leukemic Mutations Create 'Therapeutic Window' for Spliceosome Modulators

Leukemic Mutations Create 'Therapeutic Window' for Spliceosome Modulators

By

Spliceosomal-mutant leukemias displayed greater sensitivity to pharmacologic modulation of splicing than their wildtype counterparts.

Addition of Rituximab Significantly Improved Treatment of Patients With B-cell Non-Hodgkin Lymphoma

Addition of Rituximab Significantly Improved Treatment of Patients With B-cell Non-Hodgkin Lymphoma

By

A new randomized study has evaluated the addition of rituximab to the pediatric-inspired GRAALL protocol for adults with acute lymphoblastic leukemia.

High Remission Rate Seen With Arsenic Trioxide Consolidation for Children With Acute Promyelocytic Leukemia

High Remission Rate Seen With Arsenic Trioxide Consolidation for Children With Acute Promyelocytic Leukemia

By

Increased rates of event-free surviva were seen with lthe use of arsenic trioxide consolidation for children newly diagnosed with acute promyelocytic leukemia (APL).

TARC Confirmed as Biomarker of Response to PET, Brentuximab Vedotin in Hodgkin Lymphoma

TARC Confirmed as Biomarker of Response to PET, Brentuximab Vedotin in Hodgkin Lymphoma

By

TARC levels correlated with PET-normalization in certain patients with Hodgkin lymphoma treated with brentuximab vedotin, a study indicates.

Clofarabine Inferior to Standard of Care in Older Patients Newly Diagnosed with AML

Clofarabine Inferior to Standard of Care in Older Patients Newly Diagnosed with AML

By

Single-agent clofarabine is was effective for older patients with newly diagnosed acute myeloid leukemia than standard therapy combined with daunorubicin and cytarabine.

Paying for 'Value' By Defining 'Quality' and 'Cost'

Paying for 'Value' By Defining 'Quality' and 'Cost'

By

A presentation during the 57th American Society of Hematology (ASH) Annual Meeting examined the pros and cons of value-based purchasing.

PD-L1, PD-L2 Genetic Alterations Predict Outcome in Classical Hodgkin Lymphoma

PD-L1, PD-L2 Genetic Alterations Predict Outcome in Classical Hodgkin Lymphoma

By

A study has reaffirmed the importance of genetically defined PD-1 mediated immune evasion for patients with Hodgkin lymphoma.

TKI Withdrawal Linked to Osteoarticular Pain

TKI Withdrawal Linked to Osteoarticular Pain

By

Nearly 25 percent of patients with chronic myeloid leukemia (CML) undergoing treatment with tyrosine kinase inhibitors are vulnerable to a a "withdrawal syndrome," a recent study reported.

For Best Responses, Use Therapeutic Drug Monitoring to Individualize Daily Imatinib

For Best Responses, Use Therapeutic Drug Monitoring to Individualize Daily Imatinib

By

Research indicates that adjustment of imatinib doses based on therapeutic drug monitoring can result in higher rates of major molecular response in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.

High-Dose Methotrexate Confirmed for Adult Ph- ALL Use

High-Dose Methotrexate Confirmed for Adult Ph- ALL Use

By

Treatment with high-dose methotrexate was linked to significantly higher rates of disease-free survival in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL), according to results from a recent phase 3 trial.

6MP Self-Reporting in Acute Lymphoblastic Leukemia Deemed 'Unreliable'

6MP Self-Reporting in Acute Lymphoblastic Leukemia Deemed 'Unreliable'

By

Subjective over-reporting of 6-mercaptopurine (6MP) intake during maintenance therapy for childhood acute lymphoblastic leukemia is common, according to a new cohort study.

Inotuzumab Ozogamicin + Low-Intensity Chemo Effective in Older Patients with ALL

Inotuzumab Ozogamicin + Low-Intensity Chemo Effective in Older Patients with ALL

By

Inotuzumab ozogamicin combined with low-intensity mini-hyper-CVD chemotherapy has demonstrated encouraging results in older patients with acute lymphoblastic leukemia, according to data from an ongoing study.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs